JP6312302B2 - 脳梗塞の診断マーカー - Google Patents
脳梗塞の診断マーカー Download PDFInfo
- Publication number
- JP6312302B2 JP6312302B2 JP2014000417A JP2014000417A JP6312302B2 JP 6312302 B2 JP6312302 B2 JP 6312302B2 JP 2014000417 A JP2014000417 A JP 2014000417A JP 2014000417 A JP2014000417 A JP 2014000417A JP 6312302 B2 JP6312302 B2 JP 6312302B2
- Authority
- JP
- Japan
- Prior art keywords
- cerebral infarction
- seq
- infarction
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010008118 cerebral infarction Diseases 0.000 title claims description 65
- 208000026106 cerebrovascular disease Diseases 0.000 title claims description 64
- 239000003550 marker Substances 0.000 title claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 description 37
- 108091007433 antigens Proteins 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 32
- 238000000034 method Methods 0.000 description 29
- 239000000427 antigen Substances 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 15
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 10
- 210000001124 body fluid Anatomy 0.000 description 9
- 101000825071 Homo sapiens Sclerostin domain-containing protein 1 Proteins 0.000 description 8
- 102100022432 Sclerostin domain-containing protein 1 Human genes 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 102100028906 Catenin delta-1 Human genes 0.000 description 7
- 102100026099 Claudin domain-containing protein 1 Human genes 0.000 description 7
- 101000916264 Homo sapiens Catenin delta-1 Proteins 0.000 description 7
- 101000912657 Homo sapiens Claudin domain-containing protein 1 Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000012815 AlphaLISA Methods 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 102100038250 Cyclin-G2 Human genes 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- 101000884216 Homo sapiens Cyclin-G2 Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 229940112869 bone morphogenetic protein Drugs 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 for example Substances 0.000 description 4
- 238000003317 immunochromatography Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102000004030 Cyclin G2 Human genes 0.000 description 1
- 108090000487 Cyclin G2 Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 230000020172 G2/M transition checkpoint Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 108010023562 beta 2-Glycoprotein I Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical class [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014000417A JP6312302B2 (ja) | 2014-01-06 | 2014-01-06 | 脳梗塞の診断マーカー |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014000417A JP6312302B2 (ja) | 2014-01-06 | 2014-01-06 | 脳梗塞の診断マーカー |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018050502A Division JP6499342B2 (ja) | 2018-03-19 | 2018-03-19 | 脳梗塞の診断マーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015129652A JP2015129652A (ja) | 2015-07-16 |
| JP2015129652A5 JP2015129652A5 (enrdf_load_stackoverflow) | 2017-06-22 |
| JP6312302B2 true JP6312302B2 (ja) | 2018-04-18 |
Family
ID=53760486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014000417A Active JP6312302B2 (ja) | 2014-01-06 | 2014-01-06 | 脳梗塞の診断マーカー |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6312302B2 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6942036B2 (ja) * | 2017-11-30 | 2021-09-29 | 藤倉化成株式会社 | 脳梗塞の発症リスクを高感度に検出する体液抗体バイオマーカー |
| CN114594273B (zh) * | 2022-05-09 | 2024-02-27 | 上海众启生物科技有限公司 | 一种脑梗塞生物标记物及其应用 |
| CN115261457B (zh) * | 2022-06-13 | 2023-10-27 | 广州市妇女儿童医疗中心 | 用于辅助诊断脑梗塞及其预后评价的标志物组合及含有其的试剂盒与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4070443B2 (ja) * | 2001-10-11 | 2008-04-02 | 株式会社三菱化学ヤトロン | 脳梗塞を検出する方法 |
| GB0911060D0 (en) * | 2009-06-26 | 2009-08-12 | Ge Healthcare Uk Ltd | Methods for predicting the toxicity of a chemical |
| US20120040858A1 (en) * | 2010-08-13 | 2012-02-16 | Morehouse School Of Medicine | Biomarkers for stroke |
| WO2012051519A2 (en) * | 2010-10-14 | 2012-04-19 | The Johns Hopkins University | Biomarkers of brain injury |
| GB2497138A (en) * | 2011-12-02 | 2013-06-05 | Randox Lab Ltd | Biomarkers for stroke and stroke subtype diagnosis. |
| WO2013144957A1 (en) * | 2012-03-26 | 2013-10-03 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
-
2014
- 2014-01-06 JP JP2014000417A patent/JP6312302B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015129652A (ja) | 2015-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11199549B2 (en) | MEl'hods and means for diagnosing spondylarthritis using autoantibody markers | |
| US20220155296A1 (en) | Peptides, Reagents And Methods For Detecting Food Allergy | |
| US20200348304A1 (en) | Immunoassay and antibodies for the detection of chromogranin a | |
| US11609237B2 (en) | Marker sequences for diagnosing and stratifying systemic sclerosis patients | |
| EP2330420B1 (en) | Diagnosis method and diagnosis kit for clinical amyopathic dermatomyositis | |
| US20250208144A1 (en) | Assay for long forms of cardiac troponin t | |
| JP6312302B2 (ja) | 脳梗塞の診断マーカー | |
| JP6499342B2 (ja) | 脳梗塞の診断マーカー | |
| CN112166323A (zh) | 自身抗体的直接免疫测定测量 | |
| US20140234878A1 (en) | Composition for diagnosing acute myocardial infarction, kit for diagnosing acute myocardial infarction comprising same, and method of diagnosing acute myocardial infarction | |
| JP4685369B2 (ja) | 関節リウマチ診断用試薬 | |
| JP2010528306A (ja) | 心筋梗塞の早期予測因子としてのｈ−ｆａｂｐ | |
| JP5307141B2 (ja) | 心筋梗塞の早期予測因子としてのミオグロビン | |
| Infantino et al. | Current technologies for anti-ENA antibody detection: State-of-the-art of diagnostic immunoassays | |
| JP7523129B2 (ja) | ヘリコバクター・ピロリ菌株の同定方法、および同定用キット | |
| US20220276243A1 (en) | Inflammatory bowel disease diagnosis method, diagnosis probe and diagnosis kit | |
| US10036746B2 (en) | Method for the diagnosis of neuromyelitis optica | |
| Wolgast | Laboratory Diagnosis of Lupus Anticoagulant and Antiphospholipid Antibodies | |
| EP4314834B1 (en) | Diagnosis of alzheimer's disease by detecting auto-antibodies against y-box binding protein-1 (yb-1) | |
| US20240310374A1 (en) | Marker for lymphocytic adenohypophysitis and related diseases, and use of the marker | |
| Herries et al. | Brain biomarkers: follow-up of RNA expression discovery approach: CSF assays for neurogranin, SNAP-25, and VILIP-1 | |
| US20250208131A1 (en) | Diagnosis of Congenital Heart Block | |
| US20250283892A1 (en) | Diagnosis of alzheimer's disease by detecting auto-antibodies against y-box binding protein-1 (yb-1) | |
| KR20180023563A (ko) | 측방유동 면역 분석 기반의 항ccp 항체 및 류마티스인자를 이용한 류마티스 관절염 진단 방법 | |
| US20110014638A1 (en) | Soluble fas in acute coronary syndromes diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161129 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161129 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170428 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170804 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170822 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171013 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180220 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180319 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6312302 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |